Compare MAIA & CNVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MAIA | CNVS |
|---|---|---|
| Founded | 2018 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Consumer Electronics/Video Chains |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.3M | 65.5M |
| IPO Year | 2022 | 2016 |
| Metric | MAIA | CNVS |
|---|---|---|
| Price | $1.57 | $2.75 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | ★ 1.1M | 461.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 29.53 | ★ 108.99 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $78,181,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $84.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 59.13 |
| 52 Week Low | $0.87 | $1.77 |
| 52 Week High | $3.19 | $7.39 |
| Indicator | MAIA | CNVS |
|---|---|---|
| Relative Strength Index (RSI) | 39.59 | 49.95 |
| Support Level | $1.20 | $2.37 |
| Resistance Level | $1.69 | $3.49 |
| Average True Range (ATR) | 0.18 | 0.25 |
| MACD | -0.07 | -0.03 |
| Stochastic Oscillator | 17.13 | 11.11 |
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
Cineverse Corp is a main streaming technology and entertainment company. Its core business operates as a portfolio of owned and operated streaming channels with enthusiast fan bases; a large-scale aggregator and full-service distributor of feature films and television programs; and a proprietary technology software-as-a-service platform for over-the-top (OTT) app development and content distribution through subscription video-on-demand (SVOD), dedicated ad-supported (AVOD), ad-supported streaming linear (FAST) channels, social video streaming services, and audio podcasts. It generates revenue from streaming and digital, Base distribution, Podcast and other, and Other non-recurring.